---
_id: '8927'
abstract:
- lang: eng
  text: The recent outbreak of coronavirus disease 2019 (COVID‐19), caused by the
    Severe Acute Respiratory Syndrome Coronavirus‐2 (SARS‐CoV‐2) has resulted in a
    world‐wide pandemic. Disseminated lung injury with the development of acute respiratory
    distress syndrome (ARDS) is the main cause of mortality in COVID‐19. Although
    liver failure does not seem to occur in the absence of pre‐existing liver disease,
    hepatic involvement in COVID‐19 may correlate with overall disease severity and
    serve as a prognostic factor for the development of ARDS. The spectrum of liver
    injury in COVID‐19 may range from direct infection by SARS‐CoV‐2, indirect involvement
    by systemic inflammation, hypoxic changes, iatrogenic causes such as drugs and
    ventilation to exacerbation of underlying liver disease. This concise review discusses
    the potential pathophysiological mechanisms for SARS‐CoV‐2 hepatic tropism as
    well as acute and possibly long‐term liver injury in COVID‐19.
acknowledgement: This work was supported by grant F7310‐B21 from the Austrian Science
  Foundation (to MT). We thank Jelena Remetic, Claudia D. Fuchs, Veronika Mlitz and
  Daniel Steinacher, for their valuable input and discussion. Figure 1 and Figure
  2 have been created with BioRender.com.
article_processing_charge: No
article_type: original
author:
- first_name: Alexander D.
  full_name: Nardo, Alexander D.
  last_name: Nardo
- first_name: Mathias
  full_name: Schneeweiss-Gleixner, Mathias
  last_name: Schneeweiss-Gleixner
- first_name: May M
  full_name: Bakail, May M
  id: FB3C3F8E-522F-11EA-B186-22963DDC885E
  last_name: Bakail
  orcid: 0000-0002-9592-1587
- first_name: Emmanuel D.
  full_name: Dixon, Emmanuel D.
  last_name: Dixon
- first_name: Sigurd F.
  full_name: Lax, Sigurd F.
  last_name: Lax
- first_name: Michael
  full_name: Trauner, Michael
  last_name: Trauner
citation:
  ama: Nardo AD, Schneeweiss-Gleixner M, Bakail MM, Dixon ED, Lax SF, Trauner M. Pathophysiological
    mechanisms of liver injury in COVID-19. <i>Liver International</i>. 2021;41(1):20-32.
    doi:<a href="https://doi.org/10.1111/liv.14730">10.1111/liv.14730</a>
  apa: Nardo, A. D., Schneeweiss-Gleixner, M., Bakail, M. M., Dixon, E. D., Lax, S.
    F., &#38; Trauner, M. (2021). Pathophysiological mechanisms of liver injury in
    COVID-19. <i>Liver International</i>. Wiley. <a href="https://doi.org/10.1111/liv.14730">https://doi.org/10.1111/liv.14730</a>
  chicago: Nardo, Alexander D., Mathias Schneeweiss-Gleixner, May M Bakail, Emmanuel
    D. Dixon, Sigurd F. Lax, and Michael Trauner. “Pathophysiological Mechanisms of
    Liver Injury in COVID-19.” <i>Liver International</i>. Wiley, 2021. <a href="https://doi.org/10.1111/liv.14730">https://doi.org/10.1111/liv.14730</a>.
  ieee: A. D. Nardo, M. Schneeweiss-Gleixner, M. M. Bakail, E. D. Dixon, S. F. Lax,
    and M. Trauner, “Pathophysiological mechanisms of liver injury in COVID-19,” <i>Liver
    International</i>, vol. 41, no. 1. Wiley, pp. 20–32, 2021.
  ista: Nardo AD, Schneeweiss-Gleixner M, Bakail MM, Dixon ED, Lax SF, Trauner M.
    2021. Pathophysiological mechanisms of liver injury in COVID-19. Liver International.
    41(1), 20–32.
  mla: Nardo, Alexander D., et al. “Pathophysiological Mechanisms of Liver Injury
    in COVID-19.” <i>Liver International</i>, vol. 41, no. 1, Wiley, 2021, pp. 20–32,
    doi:<a href="https://doi.org/10.1111/liv.14730">10.1111/liv.14730</a>.
  short: A.D. Nardo, M. Schneeweiss-Gleixner, M.M. Bakail, E.D. Dixon, S.F. Lax, M.
    Trauner, Liver International 41 (2021) 20–32.
date_created: 2020-12-06T23:01:16Z
date_published: 2021-01-01T00:00:00Z
date_updated: 2023-08-04T11:19:51Z
day: '01'
ddc:
- '570'
department:
- _id: CampIT
doi: 10.1111/liv.14730
external_id:
  isi:
  - '000594239200001'
file:
- access_level: open_access
  checksum: 6e4f21b77ef22c854e016240974fc473
  content_type: application/pdf
  creator: dernst
  date_created: 2021-02-04T12:01:45Z
  date_updated: 2021-02-04T12:01:45Z
  file_id: '9091'
  file_name: 2021_Liver_Nardo.pdf
  file_size: 930414
  relation: main_file
  success: 1
file_date_updated: 2021-02-04T12:01:45Z
has_accepted_license: '1'
intvolume: '        41'
isi: 1
issue: '1'
language:
- iso: eng
month: '01'
oa: 1
oa_version: Published Version
page: 20-32
publication: Liver International
publication_identifier:
  eissn:
  - '14783231'
  issn:
  - '14783223'
publication_status: published
publisher: Wiley
quality_controlled: '1'
scopus_import: '1'
status: public
title: Pathophysiological mechanisms of liver injury in COVID-19
tmp:
  image: /images/cc_by.png
  legal_code_url: https://creativecommons.org/licenses/by/4.0/legalcode
  name: Creative Commons Attribution 4.0 International Public License (CC-BY 4.0)
  short: CC BY (4.0)
type: journal_article
user_id: 4359f0d1-fa6c-11eb-b949-802e58b17ae8
volume: 41
year: '2021'
...
---
_id: '9262'
abstract:
- lang: eng
  text: Sequence-specific oligomers with predictable folding patterns, i.e., foldamers,
    provide new opportunities to mimic α-helical peptides and design inhibitors of
    protein-protein interactions. One major hurdle of this strategy is to retain the
    correct orientation of key side chains involved in protein surface recognition.
    Here, we show that the structural plasticity of a foldamer backbone may notably
    contribute to the required spatial adjustment for optimal interaction with the
    protein surface. By using oligoureas as α helix mimics, we designed a foldamer/peptide
    hybrid inhibitor of histone chaperone ASF1, a key regulator of chromatin dynamics.
    The crystal structure of its complex with ASF1 reveals a notable plasticity of
    the urea backbone, which adapts to the ASF1 surface to maintain the same binding
    interface. One additional benefit of generating ASF1 ligands with nonpeptide oligourea
    segments is the resistance to proteolysis in human plasma, which was highly improved
    compared to the cognate α-helical peptide.
acknowledgement: 'We thank the Synchrotron SOLEIL, the European Synchrotron Radiation
  Facility (ESRF), and the French Infrastructure for Integrated Structural Biology
  (FRISBI) ANR-10-INBS-05. We are particularly grateful to A. Clavier and A. Campalans
  for help in setting up and performing the cell penetration assays. Funding: Research
  was funded by the French Centre National de Recherche Scientifique (CNRS), the Commissariat
  à l’Energie Atomique (CEA), University of Bordeaux, University Paris-Saclay, and
  the Synchrotron Soleil. The project was supported by the ANR 2007 BREAKABOUND (JC-07-216078),
  2011 BIPBIP (ANR-10-BINF-0003), 2012 CHAPINHIB (ANR-12-BSV5-0022-01), 2015 CHIPSET
  (ANR-15-CE11-008-01), 2015 HIMPP2I (ANR-15-CE07-0010), and the program labeled by
  the ARC foundation 2016 PGA1*20160203953). M.B. was supported by Canceropole (Paris,
  France) and a grant for young researchers from La Ligue contre le Cancer. J.M. was
  supported by La Ligue contre le Cancer.'
article_number: eabd9153
article_processing_charge: No
article_type: original
author:
- first_name: Johanne
  full_name: Mbianda, Johanne
  last_name: Mbianda
- first_name: May M
  full_name: Bakail, May M
  id: FB3C3F8E-522F-11EA-B186-22963DDC885E
  last_name: Bakail
  orcid: 0000-0002-9592-1587
- first_name: Christophe
  full_name: André, Christophe
  last_name: André
- first_name: Gwenaëlle
  full_name: Moal, Gwenaëlle
  last_name: Moal
- first_name: Marie E.
  full_name: Perrin, Marie E.
  last_name: Perrin
- first_name: Guillaume
  full_name: Pinna, Guillaume
  last_name: Pinna
- first_name: Raphaël
  full_name: Guerois, Raphaël
  last_name: Guerois
- first_name: Francois
  full_name: Becher, Francois
  last_name: Becher
- first_name: Pierre
  full_name: Legrand, Pierre
  last_name: Legrand
- first_name: Seydou
  full_name: Traoré, Seydou
  last_name: Traoré
- first_name: Céline
  full_name: Douat, Céline
  last_name: Douat
- first_name: Gilles
  full_name: Guichard, Gilles
  last_name: Guichard
- first_name: Françoise
  full_name: Ochsenbein, Françoise
  last_name: Ochsenbein
citation:
  ama: Mbianda J, Bakail MM, André C, et al. Optimal anchoring of a foldamer inhibitor
    of ASF1 histone chaperone through backbone plasticity. <i>Science Advances</i>.
    2021;7(12). doi:<a href="https://doi.org/10.1126/sciadv.abd9153">10.1126/sciadv.abd9153</a>
  apa: Mbianda, J., Bakail, M. M., André, C., Moal, G., Perrin, M. E., Pinna, G.,
    … Ochsenbein, F. (2021). Optimal anchoring of a foldamer inhibitor of ASF1 histone
    chaperone through backbone plasticity. <i>Science Advances</i>. American Association
    for the Advancement of Science. <a href="https://doi.org/10.1126/sciadv.abd9153">https://doi.org/10.1126/sciadv.abd9153</a>
  chicago: Mbianda, Johanne, May M Bakail, Christophe André, Gwenaëlle Moal, Marie
    E. Perrin, Guillaume Pinna, Raphaël Guerois, et al. “Optimal Anchoring of a Foldamer
    Inhibitor of ASF1 Histone Chaperone through Backbone Plasticity.” <i>Science Advances</i>.
    American Association for the Advancement of Science, 2021. <a href="https://doi.org/10.1126/sciadv.abd9153">https://doi.org/10.1126/sciadv.abd9153</a>.
  ieee: J. Mbianda <i>et al.</i>, “Optimal anchoring of a foldamer inhibitor of ASF1
    histone chaperone through backbone plasticity,” <i>Science Advances</i>, vol.
    7, no. 12. American Association for the Advancement of Science, 2021.
  ista: Mbianda J, Bakail MM, André C, Moal G, Perrin ME, Pinna G, Guerois R, Becher
    F, Legrand P, Traoré S, Douat C, Guichard G, Ochsenbein F. 2021. Optimal anchoring
    of a foldamer inhibitor of ASF1 histone chaperone through backbone plasticity.
    Science Advances. 7(12), eabd9153.
  mla: Mbianda, Johanne, et al. “Optimal Anchoring of a Foldamer Inhibitor of ASF1
    Histone Chaperone through Backbone Plasticity.” <i>Science Advances</i>, vol.
    7, no. 12, eabd9153, American Association for the Advancement of Science, 2021,
    doi:<a href="https://doi.org/10.1126/sciadv.abd9153">10.1126/sciadv.abd9153</a>.
  short: J. Mbianda, M.M. Bakail, C. André, G. Moal, M.E. Perrin, G. Pinna, R. Guerois,
    F. Becher, P. Legrand, S. Traoré, C. Douat, G. Guichard, F. Ochsenbein, Science
    Advances 7 (2021).
date_created: 2021-03-22T07:14:03Z
date_published: 2021-03-19T00:00:00Z
date_updated: 2023-08-07T14:20:26Z
day: '19'
ddc:
- '570'
department:
- _id: CampIT
doi: 10.1126/sciadv.abd9153
external_id:
  isi:
  - '000633443000011'
  pmid:
  - '33741589'
file:
- access_level: open_access
  checksum: 737624cd0e630ffa7c52797a690500e3
  content_type: application/pdf
  creator: dernst
  date_created: 2021-03-22T12:49:00Z
  date_updated: 2021-03-22T12:49:00Z
  file_id: '9280'
  file_name: 2021_ScienceAdv_Mbianda.pdf
  file_size: 837156
  relation: main_file
  success: 1
file_date_updated: 2021-03-22T12:49:00Z
has_accepted_license: '1'
intvolume: '         7'
isi: 1
issue: '12'
language:
- iso: eng
month: '03'
oa: 1
oa_version: Published Version
pmid: 1
publication: Science Advances
publication_identifier:
  issn:
  - 2375-2548
publication_status: published
publisher: American Association for the Advancement of Science
quality_controlled: '1'
status: public
title: Optimal anchoring of a foldamer inhibitor of ASF1 histone chaperone through
  backbone plasticity
tmp:
  image: /images/cc_by_nc.png
  legal_code_url: https://creativecommons.org/licenses/by-nc/4.0/legalcode
  name: Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0)
  short: CC BY-NC (4.0)
type: journal_article
user_id: 4359f0d1-fa6c-11eb-b949-802e58b17ae8
volume: 7
year: '2021'
...
---
_id: '9016'
abstract:
- lang: eng
  text: Inhibiting the histone H3–ASF1 (anti‐silencing function 1) protein–protein
    interaction (PPI) represents a potential approach for treating numerous cancers.
    As an α‐helix‐mediated PPI, constraining the key histone H3 helix (residues 118–135)
    is a strategy through which chemical probes might be elaborated to test this hypothesis.
    In this work, variant H3118–135 peptides bearing pentenylglycine residues at the
    i and i+4 positions were constrained by olefin metathesis. Biophysical analyses
    revealed that promotion of a bioactive helical conformation depends on the position
    at which the constraint is introduced, but that the potency of binding towards
    ASF1 is unaffected by the constraint and instead that enthalpy–entropy compensation
    occurs.
article_processing_charge: No
article_type: original
author:
- first_name: May M
  full_name: Bakail, May M
  id: FB3C3F8E-522F-11EA-B186-22963DDC885E
  last_name: Bakail
  orcid: 0000-0002-9592-1587
- first_name: Silvia
  full_name: Rodriguez‐Marin, Silvia
  last_name: Rodriguez‐Marin
- first_name: Zsófia
  full_name: Hegedüs, Zsófia
  last_name: Hegedüs
- first_name: Marie E.
  full_name: Perrin, Marie E.
  last_name: Perrin
- first_name: Françoise
  full_name: Ochsenbein, Françoise
  last_name: Ochsenbein
- first_name: Andrew J.
  full_name: Wilson, Andrew J.
  last_name: Wilson
citation:
  ama: Bakail MM, Rodriguez‐Marin S, Hegedüs Z, Perrin ME, Ochsenbein F, Wilson AJ.
    Recognition of ASF1 by using hydrocarbon‐constrained peptides. <i>ChemBioChem</i>.
    2019;20(7):891-895. doi:<a href="https://doi.org/10.1002/cbic.201800633">10.1002/cbic.201800633</a>
  apa: Bakail, M. M., Rodriguez‐Marin, S., Hegedüs, Z., Perrin, M. E., Ochsenbein,
    F., &#38; Wilson, A. J. (2019). Recognition of ASF1 by using hydrocarbon‐constrained
    peptides. <i>ChemBioChem</i>. Wiley. <a href="https://doi.org/10.1002/cbic.201800633">https://doi.org/10.1002/cbic.201800633</a>
  chicago: Bakail, May M, Silvia Rodriguez‐Marin, Zsófia Hegedüs, Marie E. Perrin,
    Françoise Ochsenbein, and Andrew J. Wilson. “Recognition of ASF1 by Using Hydrocarbon‐constrained
    Peptides.” <i>ChemBioChem</i>. Wiley, 2019. <a href="https://doi.org/10.1002/cbic.201800633">https://doi.org/10.1002/cbic.201800633</a>.
  ieee: M. M. Bakail, S. Rodriguez‐Marin, Z. Hegedüs, M. E. Perrin, F. Ochsenbein,
    and A. J. Wilson, “Recognition of ASF1 by using hydrocarbon‐constrained peptides,”
    <i>ChemBioChem</i>, vol. 20, no. 7. Wiley, pp. 891–895, 2019.
  ista: Bakail MM, Rodriguez‐Marin S, Hegedüs Z, Perrin ME, Ochsenbein F, Wilson AJ.
    2019. Recognition of ASF1 by using hydrocarbon‐constrained peptides. ChemBioChem.
    20(7), 891–895.
  mla: Bakail, May M., et al. “Recognition of ASF1 by Using Hydrocarbon‐constrained
    Peptides.” <i>ChemBioChem</i>, vol. 20, no. 7, Wiley, 2019, pp. 891–95, doi:<a
    href="https://doi.org/10.1002/cbic.201800633">10.1002/cbic.201800633</a>.
  short: M.M. Bakail, S. Rodriguez‐Marin, Z. Hegedüs, M.E. Perrin, F. Ochsenbein,
    A.J. Wilson, ChemBioChem 20 (2019) 891–895.
date_created: 2021-01-19T10:59:14Z
date_published: 2019-04-01T00:00:00Z
date_updated: 2023-02-23T13:46:48Z
day: '01'
doi: 10.1002/cbic.201800633
extern: '1'
intvolume: '        20'
issue: '7'
language:
- iso: eng
main_file_link:
- open_access: '1'
  url: ' https://doi.org/10.1002/cbic.201800633'
month: '04'
oa: 1
oa_version: Published Version
page: 891-895
publication: ChemBioChem
publication_identifier:
  issn:
  - 1439-4227
  - 1439-7633
publication_status: published
publisher: Wiley
quality_controlled: '1'
status: public
title: Recognition of ASF1 by using hydrocarbon‐constrained peptides
type: journal_article
user_id: 2DF688A6-F248-11E8-B48F-1D18A9856A87
volume: 20
year: '2019'
...
---
_id: '9018'
abstract:
- lang: eng
  text: Anti-silencing function 1 (ASF1) is a conserved H3-H4 histone chaperone involved
    in histone dynamics during replication, transcription, and DNA repair. Overexpressed
    in proliferating tissues including many tumors, ASF1 has emerged as a promising
    therapeutic target. Here, we combine structural, computational, and biochemical
    approaches to design peptides that inhibit the ASF1-histone interaction. Starting
    from the structure of the human ASF1-histone complex, we developed a rational
    design strategy combining epitope tethering and optimization of interface contacts
    to identify a potent peptide inhibitor with a dissociation constant of 3 nM. When
    introduced into cultured cells, the inhibitors impair cell proliferation, perturb
    cell-cycle progression, and reduce cell migration and invasion in a manner commensurate
    with their affinity for ASF1. Finally, we find that direct injection of the most
    potent ASF1 peptide inhibitor in mouse allografts reduces tumor growth. Our results
    open new avenues to use ASF1 inhibitors as promising leads for cancer therapy.
article_processing_charge: No
article_type: original
author:
- first_name: May M
  full_name: Bakail, May M
  id: FB3C3F8E-522F-11EA-B186-22963DDC885E
  last_name: Bakail
  orcid: 0000-0002-9592-1587
- first_name: Albane
  full_name: Gaubert, Albane
  last_name: Gaubert
- first_name: Jessica
  full_name: Andreani, Jessica
  last_name: Andreani
- first_name: Gwenaëlle
  full_name: Moal, Gwenaëlle
  last_name: Moal
- first_name: Guillaume
  full_name: Pinna, Guillaume
  last_name: Pinna
- first_name: Ekaterina
  full_name: Boyarchuk, Ekaterina
  last_name: Boyarchuk
- first_name: Marie-Cécile
  full_name: Gaillard, Marie-Cécile
  last_name: Gaillard
- first_name: Regis
  full_name: Courbeyrette, Regis
  last_name: Courbeyrette
- first_name: Carl
  full_name: Mann, Carl
  last_name: Mann
- first_name: Jean-Yves
  full_name: Thuret, Jean-Yves
  last_name: Thuret
- first_name: Bérengère
  full_name: Guichard, Bérengère
  last_name: Guichard
- first_name: Brice
  full_name: Murciano, Brice
  last_name: Murciano
- first_name: Nicolas
  full_name: Richet, Nicolas
  last_name: Richet
- first_name: Adeline
  full_name: Poitou, Adeline
  last_name: Poitou
- first_name: Claire
  full_name: Frederic, Claire
  last_name: Frederic
- first_name: Marie-Hélène
  full_name: Le Du, Marie-Hélène
  last_name: Le Du
- first_name: Morgane
  full_name: Agez, Morgane
  last_name: Agez
- first_name: Caroline
  full_name: Roelants, Caroline
  last_name: Roelants
- first_name: Zachary A.
  full_name: Gurard-Levin, Zachary A.
  last_name: Gurard-Levin
- first_name: Geneviève
  full_name: Almouzni, Geneviève
  last_name: Almouzni
- first_name: Nadia
  full_name: Cherradi, Nadia
  last_name: Cherradi
- first_name: Raphael
  full_name: Guerois, Raphael
  last_name: Guerois
- first_name: Françoise
  full_name: Ochsenbein, Françoise
  last_name: Ochsenbein
citation:
  ama: Bakail MM, Gaubert A, Andreani J, et al. Design on a rational basis of high-affinity
    peptides inhibiting the histone chaperone ASF1. <i>Cell Chemical Biology</i>.
    2019;26(11):1573-1585.e10. doi:<a href="https://doi.org/10.1016/j.chembiol.2019.09.002">10.1016/j.chembiol.2019.09.002</a>
  apa: Bakail, M. M., Gaubert, A., Andreani, J., Moal, G., Pinna, G., Boyarchuk, E.,
    … Ochsenbein, F. (2019). Design on a rational basis of high-affinity peptides
    inhibiting the histone chaperone ASF1. <i>Cell Chemical Biology</i>. Elsevier.
    <a href="https://doi.org/10.1016/j.chembiol.2019.09.002">https://doi.org/10.1016/j.chembiol.2019.09.002</a>
  chicago: Bakail, May M, Albane Gaubert, Jessica Andreani, Gwenaëlle Moal, Guillaume
    Pinna, Ekaterina Boyarchuk, Marie-Cécile Gaillard, et al. “Design on a Rational
    Basis of High-Affinity Peptides Inhibiting the Histone Chaperone ASF1.” <i>Cell
    Chemical Biology</i>. Elsevier, 2019. <a href="https://doi.org/10.1016/j.chembiol.2019.09.002">https://doi.org/10.1016/j.chembiol.2019.09.002</a>.
  ieee: M. M. Bakail <i>et al.</i>, “Design on a rational basis of high-affinity peptides
    inhibiting the histone chaperone ASF1,” <i>Cell Chemical Biology</i>, vol. 26,
    no. 11. Elsevier, p. 1573–1585.e10, 2019.
  ista: Bakail MM, Gaubert A, Andreani J, Moal G, Pinna G, Boyarchuk E, Gaillard M-C,
    Courbeyrette R, Mann C, Thuret J-Y, Guichard B, Murciano B, Richet N, Poitou A,
    Frederic C, Le Du M-H, Agez M, Roelants C, Gurard-Levin ZA, Almouzni G, Cherradi
    N, Guerois R, Ochsenbein F. 2019. Design on a rational basis of high-affinity
    peptides inhibiting the histone chaperone ASF1. Cell Chemical Biology. 26(11),
    1573–1585.e10.
  mla: Bakail, May M., et al. “Design on a Rational Basis of High-Affinity Peptides
    Inhibiting the Histone Chaperone ASF1.” <i>Cell Chemical Biology</i>, vol. 26,
    no. 11, Elsevier, 2019, p. 1573–1585.e10, doi:<a href="https://doi.org/10.1016/j.chembiol.2019.09.002">10.1016/j.chembiol.2019.09.002</a>.
  short: M.M. Bakail, A. Gaubert, J. Andreani, G. Moal, G. Pinna, E. Boyarchuk, M.-C.
    Gaillard, R. Courbeyrette, C. Mann, J.-Y. Thuret, B. Guichard, B. Murciano, N.
    Richet, A. Poitou, C. Frederic, M.-H. Le Du, M. Agez, C. Roelants, Z.A. Gurard-Levin,
    G. Almouzni, N. Cherradi, R. Guerois, F. Ochsenbein, Cell Chemical Biology 26
    (2019) 1573–1585.e10.
date_created: 2021-01-19T11:04:50Z
date_published: 2019-11-21T00:00:00Z
date_updated: 2023-02-23T13:46:53Z
day: '21'
doi: 10.1016/j.chembiol.2019.09.002
extern: '1'
external_id:
  pmid:
  - '31543461'
intvolume: '        26'
issue: '11'
keyword:
- Clinical Biochemistry
- Molecular Medicine
- Biochemistry
- Molecular Biology
- Pharmacology
- Drug Discovery
language:
- iso: eng
main_file_link:
- open_access: '1'
  url: https://doi.org/10.1016/j.chembiol.2019.09.002
month: '11'
oa: 1
oa_version: Published Version
page: 1573-1585.e10
pmid: 1
publication: Cell Chemical Biology
publication_identifier:
  issn:
  - 2451-9456
publication_status: published
publisher: Elsevier
quality_controlled: '1'
status: public
title: Design on a rational basis of high-affinity peptides inhibiting the histone
  chaperone ASF1
type: journal_article
user_id: 2DF688A6-F248-11E8-B48F-1D18A9856A87
volume: 26
year: '2019'
...
---
_id: '9019'
abstract:
- lang: eng
  text: Targeting protein–protein interactions has long been considered as a very
    difficult if impossible task, but over the past decade, front lines have moved.
    The number of successful examples is exponentially growing. This review presents
    a rapid overview of recent advances in this field considering the strengths and
    weaknesses of the small molecule approaches and alternative strategies such as
    the selection or design of artificial antibodies, peptides or peptidomimetics.
- lang: fre
  text: Cibler les interactions protéine–protéine a longtemps été considéré comme
    une tâche très difficile, voire impossible, mais, depuis les dix dernières années,
    les lignes ont bougé. Le nombre d’exemples de réussites s’accroît exponentiellement.
    Cette revue présente un rapide panorama des avancées récentes dans ce domaine,
    considérant les forces et les faiblesses de l’approche « petite molécule » ainsi
    que des stratégies alternatives comme la sélection ou le design d’anticorps artificiels,
    de peptides ou de peptidomimétiques.
article_processing_charge: No
article_type: original
author:
- first_name: May M
  full_name: Bakail, May M
  id: FB3C3F8E-522F-11EA-B186-22963DDC885E
  last_name: Bakail
  orcid: 0000-0002-9592-1587
- first_name: Francoise
  full_name: Ochsenbein, Francoise
  last_name: Ochsenbein
citation:
  ama: Bakail MM, Ochsenbein F. Targeting protein–protein interactions, a wide open
    field for drug design. <i>Comptes Rendus Chimie</i>. 2016;19(1-2):19-27. doi:<a
    href="https://doi.org/10.1016/j.crci.2015.12.004">10.1016/j.crci.2015.12.004</a>
  apa: Bakail, M. M., &#38; Ochsenbein, F. (2016). Targeting protein–protein interactions,
    a wide open field for drug design. <i>Comptes Rendus Chimie</i>. Elsevier. <a
    href="https://doi.org/10.1016/j.crci.2015.12.004">https://doi.org/10.1016/j.crci.2015.12.004</a>
  chicago: Bakail, May M, and Francoise Ochsenbein. “Targeting Protein–Protein Interactions,
    a Wide Open Field for Drug Design.” <i>Comptes Rendus Chimie</i>. Elsevier, 2016.
    <a href="https://doi.org/10.1016/j.crci.2015.12.004">https://doi.org/10.1016/j.crci.2015.12.004</a>.
  ieee: M. M. Bakail and F. Ochsenbein, “Targeting protein–protein interactions, a
    wide open field for drug design,” <i>Comptes Rendus Chimie</i>, vol. 19, no. 1–2.
    Elsevier, pp. 19–27, 2016.
  ista: Bakail MM, Ochsenbein F. 2016. Targeting protein–protein interactions, a wide
    open field for drug design. Comptes Rendus Chimie. 19(1–2), 19–27.
  mla: Bakail, May M., and Francoise Ochsenbein. “Targeting Protein–Protein Interactions,
    a Wide Open Field for Drug Design.” <i>Comptes Rendus Chimie</i>, vol. 19, no.
    1–2, Elsevier, 2016, pp. 19–27, doi:<a href="https://doi.org/10.1016/j.crci.2015.12.004">10.1016/j.crci.2015.12.004</a>.
  short: M.M. Bakail, F. Ochsenbein, Comptes Rendus Chimie 19 (2016) 19–27.
date_created: 2021-01-19T11:11:54Z
date_published: 2016-02-06T00:00:00Z
date_updated: 2023-02-23T13:46:55Z
day: '06'
ddc:
- '570'
doi: 10.1016/j.crci.2015.12.004
extern: '1'
file:
- access_level: open_access
  checksum: c262814ffdbfe95900256ab9ff42cdf5
  content_type: application/pdf
  creator: dernst
  date_created: 2021-01-22T12:36:52Z
  date_updated: 2021-01-22T12:36:52Z
  file_id: '9035'
  file_name: 2016_ComptesRendueChimie_Bakail.pdf
  file_size: 2045260
  relation: main_file
  success: 1
file_date_updated: 2021-01-22T12:36:52Z
has_accepted_license: '1'
intvolume: '        19'
issue: 1-2
keyword:
- General Chemistry
- General Chemical Engineering
language:
- iso: eng
month: '02'
oa: 1
oa_version: Published Version
page: 19-27
publication: Comptes Rendus Chimie
publication_identifier:
  issn:
  - 1631-0748
publication_status: published
publisher: Elsevier
quality_controlled: '1'
status: public
title: Targeting protein–protein interactions, a wide open field for drug design
tmp:
  image: /images/cc_by_nc_nd.png
  legal_code_url: https://creativecommons.org/licenses/by-nc-nd/4.0/legalcode
  name: Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International
    (CC BY-NC-ND 4.0)
  short: CC BY-NC-ND (4.0)
type: journal_article
user_id: 2DF688A6-F248-11E8-B48F-1D18A9856A87
volume: 19
year: '2016'
...
---
_id: '9017'
abstract:
- lang: eng
  text: MCM2 is a subunit of the replicative helicase machinery shown to interact
    with histones H3 and H4 during the replication process through its N-terminal
    domain. During replication, this interaction has been proposed to assist disassembly
    and assembly of nucleosomes on DNA. However, how this interaction participates
    in crosstalk with histone chaperones at the replication fork remains to be elucidated.
    Here, we solved the crystal structure of the ternary complex between the histone-binding
    domain of Mcm2 and the histones H3-H4 at 2.9 Å resolution. Histones H3 and H4
    assemble as a tetramer in the crystal structure, but MCM2 interacts only with
    a single molecule of H3-H4. The latter interaction exploits binding surfaces that
    contact either DNA or H2B when H3-H4 dimers are incorporated in the nucleosome
    core particle. Upon binding of the ternary complex with the histone chaperone
    ASF1, the histone tetramer dissociates and both MCM2 and ASF1 interact simultaneously
    with the histones forming a 1:1:1:1 heteromeric complex. Thermodynamic analysis
    of the quaternary complex together with structural modeling support that ASF1
    and MCM2 could form a chaperoning module for histones H3 and H4 protecting them
    from promiscuous interactions. This suggests an additional function for MCM2 outside
    its helicase function as a proper histone chaperone connected to the replication
    pathway.
article_processing_charge: No
article_type: original
author:
- first_name: Nicolas
  full_name: Richet, Nicolas
  last_name: Richet
- first_name: Danni
  full_name: Liu, Danni
  last_name: Liu
- first_name: Pierre
  full_name: Legrand, Pierre
  last_name: Legrand
- first_name: Christophe
  full_name: Velours, Christophe
  last_name: Velours
- first_name: Armelle
  full_name: Corpet, Armelle
  last_name: Corpet
- first_name: Albane
  full_name: Gaubert, Albane
  last_name: Gaubert
- first_name: May M
  full_name: Bakail, May M
  id: FB3C3F8E-522F-11EA-B186-22963DDC885E
  last_name: Bakail
  orcid: 0000-0002-9592-1587
- first_name: Gwenaelle
  full_name: Moal-Raisin, Gwenaelle
  last_name: Moal-Raisin
- first_name: Raphael
  full_name: Guerois, Raphael
  last_name: Guerois
- first_name: Christel
  full_name: Compper, Christel
  last_name: Compper
- first_name: Arthur
  full_name: Besle, Arthur
  last_name: Besle
- first_name: Berengère
  full_name: Guichard, Berengère
  last_name: Guichard
- first_name: Genevieve
  full_name: Almouzni, Genevieve
  last_name: Almouzni
- first_name: Françoise
  full_name: Ochsenbein, Françoise
  last_name: Ochsenbein
citation:
  ama: Richet N, Liu D, Legrand P, et al. Structural insight into how the human helicase
    subunit MCM2 may act as a histone chaperone together with ASF1 at the replication
    fork. <i>Nucleic Acids Research</i>. 2015;43(3):1905-1917. doi:<a href="https://doi.org/10.1093/nar/gkv021">10.1093/nar/gkv021</a>
  apa: Richet, N., Liu, D., Legrand, P., Velours, C., Corpet, A., Gaubert, A., … Ochsenbein,
    F. (2015). Structural insight into how the human helicase subunit MCM2 may act
    as a histone chaperone together with ASF1 at the replication fork. <i>Nucleic
    Acids Research</i>. Oxford University Press. <a href="https://doi.org/10.1093/nar/gkv021">https://doi.org/10.1093/nar/gkv021</a>
  chicago: Richet, Nicolas, Danni Liu, Pierre Legrand, Christophe Velours, Armelle
    Corpet, Albane Gaubert, May M Bakail, et al. “Structural Insight into How the
    Human Helicase Subunit MCM2 May Act as a Histone Chaperone Together with ASF1
    at the Replication Fork.” <i>Nucleic Acids Research</i>. Oxford University Press,
    2015. <a href="https://doi.org/10.1093/nar/gkv021">https://doi.org/10.1093/nar/gkv021</a>.
  ieee: N. Richet <i>et al.</i>, “Structural insight into how the human helicase subunit
    MCM2 may act as a histone chaperone together with ASF1 at the replication fork,”
    <i>Nucleic Acids Research</i>, vol. 43, no. 3. Oxford University Press, pp. 1905–1917,
    2015.
  ista: Richet N, Liu D, Legrand P, Velours C, Corpet A, Gaubert A, Bakail MM, Moal-Raisin
    G, Guerois R, Compper C, Besle A, Guichard B, Almouzni G, Ochsenbein F. 2015.
    Structural insight into how the human helicase subunit MCM2 may act as a histone
    chaperone together with ASF1 at the replication fork. Nucleic Acids Research.
    43(3), 1905–1917.
  mla: Richet, Nicolas, et al. “Structural Insight into How the Human Helicase Subunit
    MCM2 May Act as a Histone Chaperone Together with ASF1 at the Replication Fork.”
    <i>Nucleic Acids Research</i>, vol. 43, no. 3, Oxford University Press, 2015,
    pp. 1905–17, doi:<a href="https://doi.org/10.1093/nar/gkv021">10.1093/nar/gkv021</a>.
  short: N. Richet, D. Liu, P. Legrand, C. Velours, A. Corpet, A. Gaubert, M.M. Bakail,
    G. Moal-Raisin, R. Guerois, C. Compper, A. Besle, B. Guichard, G. Almouzni, F.
    Ochsenbein, Nucleic Acids Research 43 (2015) 1905–1917.
date_created: 2021-01-19T11:01:01Z
date_published: 2015-02-18T00:00:00Z
date_updated: 2023-02-23T13:46:50Z
day: '18'
doi: 10.1093/nar/gkv021
extern: '1'
external_id:
  pmid:
  - '25618846'
intvolume: '        43'
issue: '3'
language:
- iso: eng
month: '02'
oa_version: Published Version
page: 1905-1917
pmid: 1
publication: Nucleic Acids Research
publication_identifier:
  issn:
  - 1362-4962
  - 0305-1048
publication_status: published
publisher: Oxford University Press
quality_controlled: '1'
status: public
title: Structural insight into how the human helicase subunit MCM2 may act as a histone
  chaperone together with ASF1 at the replication fork
type: journal_article
user_id: 2DF688A6-F248-11E8-B48F-1D18A9856A87
volume: 43
year: '2015'
...
